Soleno Therapeutics Receives Breakthrough Therapy Designation From FDA For DCCR Extended-Release Tablets in Prader-Willi Syndrome

Soleno Therapeutics Inc +2.67% Pre

Soleno Therapeutics Inc

SLNO

51.55

51.55

+2.67%

0.00% Pre

First Ever Breakthrough Designation for a Drug Being Developed for PWS

Designation is Based on Data from the Phase 3 Program for DCCR

Planned Submission of a New Drug Application (NDA) for DCCR Remains on Track for Mid-2024

Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via